PSMA PET/CT patterns of recurrence after mono-brachytherapy in men with low and intermediate prostate cancer and subsequent management
Brachytherapy · 2024
DOI: 10.1016/j.brachy.2024.07.003 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Brachytherapy, 2024. Verfasst von Genevieve Loos und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; Centre Jean Perrin, Clermont-Ferrand, France. Electronic addre…. Hauptthemen laut MEDLINE: Brachytherapy, Neoplasm Recurrence, Local, Prostate-Specific Antigen, Prostatic Neoplasms. Die Arbeit nennt 37 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Brachytherapy as monotherapy is a recommended treatment option for men with low to intermediate risk prostate cancer. Local recurrence is difficult to identify. This study investigated PSMA PET/CT for recurrence after brachytherapy, as well as their subsequent management when recurrence occurred only within the prostate. METHODS: We performed a retrospective single-center analysis for patients who were treated with brachytherapy as monotherapy for prostate cancer from May 2002 to May 2021 and who underwent a PSMA PET/CT for BCR. We report the findings on PSMA PET/CT, quantitative parameters, as well as the later management of the patients. RESULTS: Forty patients were identified, who underwent PSMA PET/CT to investigate a rising PSA at a median (IQR) of 7 years (3.0-10.8) after initial therapy. Median (IQR) PSA at time of PSMA PET/CT was 6.54 ng/mL (3.9-15.5). On PSMA PET/CT, 20/40 (50%) men had prostate-only recurrence. Of the 20 patients with prostate-only recurrence, 8/20 (40%) had recurrence in a high-dose radiation zone, versus 7/20 (35%) in an under-covered zone. On PSMA PET/CT, recurrence within the prostate had median (IQR) SUVmax 10.4 (5.1-15.7) and volume 2.9 mL (2.0-11.2). Subsequent management of these patients with local recurrence included surveillance followed by ADT (9/20, 45%). For those with surveillance followed by ADT, the mean time before introduction of ADT was 4.1 years (range 1-8 years).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; Centre Jean Perrin, Clermont-Ferrand, France. Electronic address: genevieve.loos@clermont.unicancer.fr.
- Prostate Cancer Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department…
- Department of Radiation Oncology, BC Cancer, Vancouver, Canada.
- Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
- Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Zitieren
APA
Loos, G., Buteau, J. P., Oh, J., Van Dyk, S., Chang, D., Murphy, D. G., Hofman, M. S., Williams, S., & Chander, S. (2024). PSMA PET/CT patterns of recurrence after mono-brachytherapy in men with low and intermediate prostate cancer and subsequent management. Brachytherapy. https://doi.org/10.1016/j.brachy.2024.07.003
Vancouver
Loos G, Buteau JP, Oh J, Van Dyk S, Chang D, Murphy DG, et al. PSMA PET/CT patterns of recurrence after mono-brachytherapy in men with low and intermediate prostate cancer and subsequent management. Brachytherapy. 2024. doi:10.1016/j.brachy.2024.07.003
BibTeX
@article{Loos2024,
author = {Loos, Genevieve and Buteau, James P and Oh, Justin and Van Dyk, Sylvia and Chang, David and Murphy, Declan G and Hofman, Michael S and Williams, Scott and Chander, Sarat},
title = {PSMA PET/CT patterns of recurrence after mono-brachytherapy in men with low and intermediate prostate cancer and subsequent management},
journal = {Brachytherapy},
year = {2024},
doi = {10.1016/j.brachy.2024.07.003}
}
EUVIMED